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1Introduction
An increasing number of studies suggest a role for lipid 
and glucose metabolism in prostate cancer (PCa) develop-
ment. Findings from a recent meta- analysis reported a 
strong positive association between obesity and risk of 
advanced prostate cancer [1], indicating that lifestyle- related 
risk factors influence PCa aggressiveness and progression. 
Nonetheless, epidemiological evidence on the association 
between other lifestyle- related risk factors, including 
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Abstract
Lifestyle- related risk factors such as hyperglycemia and dyslipidemia have been 
associated with several cancers. However, studies exploring their link with pros-
tate cancer (PCa) clinicopathological characteristics are sparse and inconclusive. 
Here, we investigated the associations between serum metabolic markers and 
PCa clinicopathological characteristics. The study comprised 14,294 men from 
the Swedish Apolipoprotein MOrtality RISk (AMORIS) cohort who were diag-
nosed with PCa between 1996 and 2011. Univariate and multivariable logistic 
regression were used to investigate the relation between glucose, triglycerides 
and total cholesterol and PCa risk categories, PSA, Gleason score, and T- stage. 
Mean age at time of PCa diagnosis was 69 years. Men with glucose levels 
>6.9 mmol/L tend to have PSA<4 μg/L, while those with glucose levels of 
5.6–6.9 mmol/L had a greater odds of PSA>20 μg/L compared to PSA 4.0–9.9 μg/L. 
Hypertriglyceridemia was also positively associated with PSA>20 μg/L. Hyper-
glycemic men had a greater odds of intermediate- and high- grade PCa and 
advanced stage or metastatic PCa. Similarly, hypertriglyceridemia was positively 
associated with high- grade PCa. There was also a trend toward an increased 
odds of intermediate risk localized PCa and advanced stage PCa among men 
with hypertriglyceridemia. Total cholesterol did not have any statistically sig-
nificant association with any of the outcomes studied. Our findings suggest that 
high serum levels of glucose and triglycerides may influence PCa aggressiveness 
and severity. Further investigation on the role of markers of glucose and lipid 
metabolism in influencing PCa aggressiveness and severity is needed as this may 
help define important targets for intervention.
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dyslipidemia and diabetes, and PCa development and 
progression remains sparse and inconclusive [2–5]. 
Moreover, most of these studies are limited by few cases, 
short follow- up time, and lack of power to detect the 
true associations between the exposures and the outcomes. 
Biologically, both dyslipidemia and hyperglycemia have 
been implicated with prostate carcinogenesis. Evidence 
from experimental studies using in vivo and in vitro 
models demonstrated that they may induce prostate car-
cinogenesis by modulating signaling pathways, which pro-
mote carcinogenic processes such as cell growth and 
proliferation, inflammation, oxidative stress, and cell migra-
tion [6–15].
Based on data in the AMORIS cohort, a large Swedish 
database with information on over 800,000 men and 
women, we have previously identified that abnormal serum 
lipid and glucose profiles may be involved in risk of 
developing PCa. Our findings showed a positive associa-
tion between hypertriglyceridemia and PCa risk in hyper-
glycemic men [16]. Conversely, we found that high- density 
lipoprotein and Apolipoprotein A- 1 were inversely associ-
ated with PCa risk [17]. Here, we further investigated 
this by evaluating the association between serum total 
cholesterol, triglycerides and glucose and PCa risk categories 
and clinicopathological characteristics (i.e., PSA, Gleason 
score, and TNM staging) in the updated AMORIS cohort.
Materials and Methods
Study design and population
Detailed description of the AMORIS cohort can be found 
elsewhere [16, 18]. Briefly, this database comprises 812,073 
Swedish men and women with blood samples sent for 
laboratory evaluation to the Central Automation Laboratory 
(CALAB) in Stockholm, Sweden, during the period 1985–
1996 [19–21]. Individuals recruited were primarily from 
the greater Stockholm area, who were either healthy and 
having laboratory testing as part of a general checkup or 
outpatients referred for laboratory testing. None of the 
participants were inpatients at the time of sampling. In 
the AMORIS cohort, the CALAB database was linked to 
several Swedish national registries such as the Swedish 
National Cancer Register, the Hospital Discharge Register, 
the Cause of Death Register, the consecutive Swedish 
Censuses during 1970–1990, and the National Register of 
Emigration using the Swedish 10- digit personal identity 
number.
For this study, we specifically focused on the linkage 
between the AMORIS database and the National Prostate 
Cancer Register (NPCR), which has been nationwide since 
1998 [22]. NPCR was developed to provide data for qual-
ity assurance and includes 98% of all newly diagnosed 
PCa cases registered in the Swedish National Cancer Register 
[22] to which reporting is mandated. From the NPCR, 
we extracted information on date of diagnosis, age at 
diagnosis, TNM stage [19], Gleason score, serum con-
centration of PSA at time of diagnosis, and primary treat-
ment given or planned up to 6 months after date of 
diagnosis. Information on educational level was retrieved 
from the Population and Housing Census for 1970–1990. 
Using information from the National Patient Register, we 
calculated the Charlson comorbidity index which includes 
19 diseases, with each disease category assigned a weight. 
The sum of an individual’s weights was used to create a 
score, resulting in four comorbidity levels ranging from 
no comorbidity to severe comorbidity (0, 1, 2, and ≥3) 
[23].
From AMORIS, we selected all men aged 20 and older 
diagnosed with PCa (and information on their prostate 
tumor characteristics from 1996 until 31 December 2011), 
who had baseline levels of serum glucose, total cholesterol, 
and triglycerides taken from the same health visit [19]. 
A total of 14,294 men were included in the final analysis. 
Figure S1 provides an overview of the cohort selection 
process.
Total cholesterol and triglycerides were measured enzy-
matically as previously described [24]. Glucose was also 
measured enzymatically with a glucose oxidase/peroxidase 
method. All methods were fully automated with automatic 
calibration and performed at one accredited laboratory 
[20].
The primary endpoints for our study are PCa risk cat-
egories. These risk categories were defined in accordance 
with an adapted version of National Comprehensive Cancer 
Network as low risk (T1- 2, Gleason score 2–6 and PSA 
<10 ng/mL), intermediate risk (T1- 2, Gleason score 7 
and/or PSA 10 to <20 ng/mL), high risk (T3 and/or 
Gleason score 8–10 and/or PSA 20 to <50 ng/mL), and 
regionally metastatic tumors (T4 and/or N1 and/or PSA 
50–<100 ng/mL in the absence of distant metastases (M0 
or MX)) and distant metastatic tumors (M1 and/or PSA 
>100 ng/mL) [22]. We also included the clinicopathologi-
cal characteristics (PSA levels, Gleason score, T stage) as 
outcomes. PSA was categorized as <4 μg/ L, 4–9.9 μg/ 
L, 10–20 μg/L and >20 μg/L. Gleason score was defined 
as low- grade tumor (Gleason score ≤6 or WHO grade 
1), intermediate grade tumor (Gleason score 7 or WHO 
grade 2) and high- grade tumor (Gleason score ≥8 or 
WHO grade 3), while T stage was defined as localized 
(T1–T2) and advanced (T3–T4).
Statistical analysis
Odds ratios and 95% confidence intervals for the associa-
tion between serum glucose, total cholesterol and 
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triglycerides and PCa clinicopathological characteristics 
were calculated using logistic regression. In multivariable 
analyses, models were adjusted for age at diagnosis, edu-
cational level (low, intermediate, high), CCI (0, 1, 2, ≥3), 
and fasting status (fasting, nonfasting, missing). For each 
man, we also calculated the interval time between the 
time from blood analyses and date of PCa diagnosis, which 
was also included as a covariate in the model. All models 
were also mutually adjusted for serum glucose, total cho-
lesterol, and triglycerides. Due to the high percentage of 
cases with missing information on body mass index (BMI) 
(78.5%), BMI was not included as a covariate in our 
multivariate model. These missing value indicators were 
included in the statistical models. We did conduct a sen-
sitivity analysis in the subgroup with information on BMI 
(n = 3073), whereby we adjusted for BMI. Due to the 
small sample size, statistical significance disappeared, but 
the directions of the associations virtually remained the 
same. We also conducted stepwise regression analyses 
among those with information on BMI to assess the effect 
of excluding BMI on the multivariate model. The results 
of our stepwise regression analyses showed that adjusting 
for BMI had little or no effect on the multivariate model, 
thus suggesting that BMI may not be an important con-
founder in this study population. Hence, all results shown 
are focused on the cohort of 14,294 men. Missing values 
were assigned to separate categories for education (1.5%) 
and fasting status (11.0%).
Serum glucose, total cholesterol, and triglycerides levels 
were analyzed using clinical cut- offs in accordance with 
the American Diabetes Association and National 
Cholesterol Education Programme (NCEP) guide-
lines[25–27]. Serum glucose levels were categorized as 
<5.6 mmol/L, 5.6–6.9 mmol/L, and >6.9 mmol/L, while 
serum total cholesterol was classified as <5.18 mmol/L, 
5.18 mmol/L–6.19 mmol/L, and >6.19 mmol/L and serum 
triglycerides as <1.7 mmol/L, 1.7–2.24 mmol/L, and 
>2.24 mmol/L. The lowest clinical cut- offs were selected 
as the reference category.
Finally, we conducted a sensitivity analysis whereby we 
excluded men with measurements taken 2 years or less 
prior to the date of PCa diagnosis to assess possible reverse 
causation. We also performed a sensitivity analysis whereby 
we excluded men with nonfasting glucose 
measurements.
Data management and statistical analyses were conducted 
with Statistical Analysis Software (SAS) release 9.4 (SAS 
Institute, Cary, NC).
Results
Table 1 illustrates the baseline characteristics of the study 
population. Mean age at PCa diagnosis was 69 ± 8.0 years. 
The median levels of glucose, total cholesterol, and tri-
glycerides at baseline were 4.9 mmol/L, 5.8 mmol/L, and 
1.2 mmol/L, respectively. Most men had normal glucose 
(<5.60 mmol/L) and triglycerides (<1.7 mmol/L) levels 
(82.5% and 69.1%, respectively), while at least 75% men 
had borderline high or high total cholesterol levels with 
mean time between measurement and PCa diagnosis of 
16.7 ± 4.8 years.
Men with glucose in the prediabetic range (5.6–
6.9 mmol/L) had a greater odds of high risk and metastatic 
cancer, as compared to normoglycemic men (OR: 1.13; 
95% CI: 0.98–1.30 and OR: 1.21; 95% CI: 1.04–1.42 for 
high risk and metastatic PCa, respectively) (Table 2). 
Triglycerides were positively associated with intermediate 
risk localized PCa for the highest versus the lowest sub-
group (OR: 1.17; 95% CI: 1.03–1.34). Positive but non-
statistically significant associations between 
hypertriglyceridemia and high risk and metastatic PCa 
were also observed. When considering total cholesterol, 
there was no evidence to suggest any differences in any 
of the outcomes studies based on serum total cholesterol 
levels.
When studying PSA as an outcome, we observed that 
a greater proportion of men with glucose levels 
>6.90 mmol/L had PSA <4 μg/L (OR: 1.43; 95% CI: 
1.01–1.45), compared to PSA levels of 4.0–9.9 μg/L. There 
was also a positive association between glucose levels of 
5.6–6.9 mmol/L and PSA levels >20 μg/L compared to 
PSA levels of 4.0–9.9 μg/L (OR: 1.28; 95% CI: 1.13–1.45) 
(Table 3). Moreover, we found a positive association 
between triglycerides ≥2.25 mmol/L and PSA levels 
>20 μg/L (OR: 1.17; 95% CI: 1.03–1.34), as compared 
to PSA levels of 4.0–9.9 μg/L.
For Gleason score, we found a positive association 
between glucose levels of 5.6–6.9 mmol/L and risk of 
intermediate- grade (OR: 1.18; 95% CI: 1.05–1.33) and 
high- grade PCa (OR: 1.24; 95% CI: 1.07–1.44) (Table 3). 
Compared to men with glucose <5.6 mmol/L, there was 
also an increased odds of high- risk PCa among men with 
glucose levels in the diabetic range (>6.9 mmol/L) (OR: 
1.37; 95%: 1.02–1.87). Hypertriglyceridemia was positively 
associated with high- grade PCa (OR: 1.17; 95% CI: 1.01–
1.37), but the odds of intermediate grade PCa did not 
appear to be different by triglycerides levels. Although 
neither glucose nor triglycerides had a statistically signifi-
cant association with stage of PCa, there was an observed 
trend toward increased odds of T3–T4 PCa with increasing 
glucose and triglycerides levels (P for trend: 0.022 and 
0.046, respectively).
The exclusion of 21 men with measurements taken less 
than 2 years prior to PCa diagnosis did not result in 
changes in the findings (Table S2 and S3). When we 
restricted our analyses to men with fasting glucose 
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measurements, the direction of the associations remained 
virtually unchanged (Table S4).
Discussion
In this study, we found evidence suggesting an independ-
ent positive association between serum glucose levels and 
higher grade (Gleason score 7 or ≥8) and advanced PCa 
(T3–T4, metastatic PCa). Similarly, men with hypertri-
glyceridemia (≥2.25 mmol/L) had increased odds of higher 
grade or more advanced PCa. When PSA was taken into 
account, we observed that men with glucose levels in the 
diabetic range (>6.9 mmol/L) had greater odds of having 
PSA levels <4 μg/L, while those with glucose levels in 
the prediabetic range (5.6–6.9 mmol/L) had greater odds 
of having PSA >20 μg/L. Men with hypertriglyceridemia 
(≥2.25 mmol/L) also had increased odds of PSA >20 μg/L. 
There was, however, no evidence to suggest that the odds 
of any of the outcomes studied varied by total cholesterol 
levels.
Glucose
Hyperglycemia has been positively associated with cancers 
such as pancreatic, breast, and colorectal cancer [28,29]. 
However, its link with prostate carcinogenesis is conflict-
ing. Consistent with our findings, four other studies found 
evidence of higher risk of more aggressive or advanced 
PCa among men with abnormal glucose levels with the 
association being nonsignificant in two of the studies [3, 
Characteristics Total population (N = 14294)
Clinical stage
N (%)
T1 6797 (47.6)
T2 4290 (30.0)
T3 2496 (17.5)
T4 319 (3.2)
Missing 392 (2.7)
N0 1502 (10.5)
N1 292 (1.0)
Missing/NX 12500 (87.5)
M0 4665 (32.6)
M1 867 (6.1)
Missing/MX 8762 (61.3)
Risk categories
N (%)
Localized
Low risk 4472 (31.3)
Intermediate risk 4032 (28.2)
High risk 3258 (22.8)
Regional/distant metastatic 2187 (15.3)
Missing 345 (2.4)
Table 1. (Continued)Table 1. Baseline characteristics of study population.
Characteristics Total population (N = 14294)
Age at diagnosis (years)
Mean (SD) 69 (8.0)
N (%)
≤49 95 (0.7)
50–59 1971 (13.8)
60–69 6321 (44.2)
≥70 5916 (41.4)
Education
High 4427 (31.0)
Intermediate 5912 (41.2)
Low 3740 (26.2)
Missing 215 (1.5)
Charlson comorbidity index
0 10651 (74.5)
1 1840 (12.9)
2 1104 (7.7)
≥3 699 (4.9)
Glucose (mmol/L)
Median (IQR) 4.9 (4.6–5.4)
N (%)
<5.60 11796 (82.5)
5.6–6.9 2062 (14.4)
>6.9 436 (3.1)
Total cholesterol (mmol/L)
Median (IQR) 5.8 (5.2–6.5)
N(%)
<5.18 3552 (24.9)
5.18–6.19 5394 (37.7)
>6.19 5348 (37.4)
Triglycerides (mmol/L)
Median (IQR) 1.2 (0.9–1.8)
N (%)
<1.70 9878 (69.1)
1.70–2.24 2199 (15.4)
≥2.25 2217 (15.5)
Fasting status
N (%)
 Fasting 8577 (60.0)
 Nonfasting 4143 (29.0)
 Missing/Unknown 1574 (11.0)
Interval time between measurement and prostate cancer diagnosis
Mean (SD) 16.7 (4.8)
PSA (μg/L)
Median (IQR) 9.4 (5.8–20.0)
N(%)
>4 1164 (8.1)
4.0–9.9 6126 (42.9)
10.0–20.0 3219 (22.5)
>20.0 3351 (23.4)
Missing 434 (3.0)
Gleason grade
N (%)
 Low 6942 (48.6)
 Intermediate 4789 (33.5)
 High 2320 (16.2)
 Missing 243 (1.7)
(Continued)
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4, 30–32]. Conversely, several other studies reported a 
protective effect of hyperglycemia or diabetes against higher 
grade or more advanced PCa [33–38]. The observed posi-
tive association reported by our study may be explained 
by several underlying biological mechanisms. For several 
decades, glucose has been documented as an important 
source of energy for rapid tumor cell proliferation [39, 
40]. Evidence from clinical and genetic studies have also 
linked the hyperglycemic environment to carcinogenic 
processes such as apoptosis, oxidative stress, DNA dam-
age, and chronic inflammation, which may drive the 
aggressiveness and progression of cancer (Fig. 1) [11–14, 
40, 41]. For instance, one mice study found that transla-
tion of the glycolytic enzyme hexokinase 2 (HK2) was 
increased in PCa cells due to loss of Pten and p53, which 
help to prevent cells from growing uncontrollably [11]. 
GLUT12, an important protein in the glycolytic pathway, 
was also observed to be highly expressed by PCacells and 
may potentially help to facilitate the high energy needs 
of tumor cells [12]. Other metabolic changes such as 
hyperinsulinemia, increased level of bioavailable IGF 1, 
and increased production of advanced glycation end prod-
ucts (AGE), which occur in response to a hyperglycemic 
environment, have also been linked to increased prolifera-
tion of cancer cells and poorer cancer outcomes [42, 43].
Furthermore, the observed positive association between 
glucose and more aggressive or advanced PCa persisted 
even after correcting for the potential confounding effects 
of BMI. Unlike most of the observational studies which 
examined the link between diabetes and PCa outcomes, 
we focused on serum glucose which has been suggested 
to be more sensitive than diabetes for accurately deter-
mining the relationship between glucose regulation and 
disease outcomes [44]. Nevertheless, in our study, we 
lacked information on duration of glucose aberrations. 
Prolonged glucose impairment has been reported to cause 
destruction of the Leydig cells, thereby, resulting in lower 
testosterone levels and potentially lowering the risk of 
worse outcomes [40, 45–48]. Nonetheless, evidence linking 
lower testosterone to reduced risk of worse PCa outcomes 
remains conflicting [46–48].
Similar to our study, one recent study reported higher 
PSA levels among prediabetic men [49]. In line with our 
findings, several studies also reported that diabetes or 
glucose in the diabetic range was associated with lower 
PSA levels [50–54]. Overall, our findings suggest that the 
effect of glucose levels in the prediabetic phase on PSA 
levels may be different from the diabetic phase. The 
potential mechanism through which prediabetes or 
impaired glucose tolerance may affect PSA levels is 
unknown. It is possible that in the prediabetic spectrum, 
the hormonal milieu characterized by hyperinsulinemia 
or higher IGF- 1 activity may play a role [41]. With regard 
to men with glucose in the diabetic range, the underlying 
mechanisms which may partly explain the observed lower 
PSA levels involve reduction in testosterone levels and 
insulin- growth factor- 1 bioactivity, resulting from hypo-
insulinemia in the long term, and the use of metformin, 
a potential antineoplastic treatment [40, 41, 55–57]. 
Additionally, obesity, which is common among men with 
abnormal glucose levels, may also have contributed to 
the observed lower PSA levels due to PSA hemodilution 
[40, 52, 58]. However, in our subgroup analyses involving 
men with information on BMI, adjusting for BMI had 
minimal or no effect on the multivariate model.
Interestingly, we also found that although among men 
with glucose in the diabetic range (>6.9 mmol/L) had 
lower PSA levels, they had a greater odds of high- grade 
or more advanced PCa. This finding may be partly due 
to the fact that men with PSA <4 μg/L are not likely to 
be biopsied and may therefore be diagnosed in the symp-
tomatic stage when the cancer is more aggressive or 
advanced. These results are also in line with other studies 
indicating that men with low- PSA producing cancers tend 
to develop very poorly differentiated or highly tumorigenic 
castration- resistant PCa cells [59–61].
Total cholesterol and triglycerides
Four prospective studies found positive associations 
between total cholesterol and higher grade or more 
advanced PCa [5, 62–65]. Comparable to our study, the 
effect was positive, but statistically significant in two of 
these studies [5, 65]. Upon adjustment for age, we observed 
that the statistical significant ORs disappeared, which is 
consistent with the well- established view that age is a 
shared risk factor for both hypercholesterolemia and cancer 
[45, 66, 67].
Previously, we provided evidence supporting a potential 
role for lipid metabolism in PCa development [16, 17]. 
Here, we provided further evidence showing that triglyc-
erides may influence the aggressiveness and severity of 
Figure 1. Schematic representation of carcinogenic processes suggested 
to be associated with hyperglycemia and dyslipidemia.
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PCa. Except for one small Japanese study, most epide-
miological studies did not report a link between triglyc-
erides and PCa prognostic outcomes [2]. However, 
experimental studies using in vitro models, have shown 
that triglyceride- rich remnant like particles induce car-
cinogenesis by upregulating cell signaling pathways, such 
as the MEK/ERK and Akt pathways, involved in control-
ling cell growth and proliferation, apoptosis, cell cycle 
arrest, and lipid biosynthesis (Fig 1) [7, 8, 68].
Consistent with results from previous studies, total 
cholesterol did not appear to have an influence on PSA 
levels [69, 70]. In contrast to our findings, one study 
including 6774 Chinese men, reported an inverse associa-
tion between triglycerides and PSA levels [71]. Two other 
studies, however, did not find any association between 
triglycerides and PSA [69, 70]. Further studies are needed 
to assess the relation between these lipids and PSA levels 
in men with PCa, as most studies to date involve healthy 
men from a relatively low- risk Asian population.
Strengths and limitations
This is one of the largest prospective studies to investigate 
the relation between glucose and lipid metabolism and 
clinicopathological characteristics of PCa. Our study popu-
lation was also selected from an almost complete population- 
based PCa register. Another strength of our study is the 
use of prediagnostic exposure measurements, which were 
all measured at a central laboratory. This enabled us to 
assess relations between the exposures and outcomes tem-
porally and minimized the potential influence of reverse 
causation. Moreover, the results of our sensitivity analyses 
did not indicate any evidence of reverse causation.
PCa is a slow- progressing cancer [72] with a long induc-
tion period estimated at 6–13 years by some studies [73]. 
In this study, the relatively long time of 16.7 years between 
exposure measurement and PCa diagnosis, which may 
reflect the induction period between the exposures and 
PCa, can also be considered as a strength. However, we 
only used a single baseline exposure measurement, pre-
cluding consideration of the effect of longitudinal changes 
in exposure level over time [33, 37]. Further studies using 
repeated measurements are therefore warranted to account 
for the potential effect of this limitation. Our study also 
lacks information on participants’ diabetic status and his-
tory of use of metformin and/or statin, so that exposure 
misclassification may have occurred. However, any such 
misclassification would be nondifferential since we used 
prediagnostic baseline exposure measurements. We did 
not have information on life- style- related factors such as 
smoking status and dietary history. Nonetheless, existing 
evidence does not appear to substantiate a link between 
the afore- mentioned lifestyle risk factors and poorer PCa 
outcomes [1]. Based on the results of our sensitivity 
analyses, the lack of information on fasting status for 
some men did not appear to influence our results. Finally, 
we lack follow- up information on the clinicopathological 
characteristics of PCa such as PSA, and therefore, could 
not evaluate the association between the studied serum 
biomarkers and PCa biochemical recurrence or PCa 
progression.
Conclusion
Our findings suggest that the potential influence of glucose 
on PSA levels may vary as one progress from the pre-
diabetic phase to the diabetic phase. Interestingly, though 
men in both the intermediate and highest glucose sub-
groups had poorer PCa outcomes. These findings may 
have important clinical implications for PCa detection 
and treatment, particularly among men with high glucose 
and low PSA levels, as previous evidence have shown 
that low PSA level is also concomitant with poorer PCa 
survival [61]. Overall, our findings further support a 
potential role for the lipid and glucose metabolism in 
prostate carcinogenesis.
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